ENTRY       D12317                      Drug
NAME        Bavunalimab (USAN/INN);
            Pavunalimab
FORMULA     C5576H8597N1481O1737S36
EXACT_MASS  125248.9856
MOL_WEIGHT  125326.1439
SEQUENCE    (Chain A)
            EVQLVESGGG LVKPGGSLRL SCAASGFTFS SYTMHWVRQA PGKGLEWVSF ISYDGNYKYY
            ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARGG HLGPFDLWGQ GTMVTVSSGK
            PGSGKPGSGK PGSGKPGSEI VLTQSPATLS LSPGERATLS CRASQSVGSS YLAWYQQKPG
            QAPRLLIYGA SSRATGIPDR FSGSGSGTDF TLTISRLEPE DFAVYYCQQY GSSPWTFGQG
            TKVEIKEPKS SDKTHTCPPC PAPPVAGPSV FLFPPKPKDT LMISRTPEVT CVVVDVKHED
            PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA
            PIEKTISKAK GQPREPQVYT LPPSREQMTK NQVKLTCLVK GFYPSDIAVE WESNGQPENN
            YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVLHE ALHSHYTQKS LSLSPGK
            (Chain B)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFD DAWMSWVRQA PGKGLEWVAE ISTKANNHAT
            	YYAESVKGRF TISRDDSKSS VYLQMNSLRA EDTAVYYCTR LATWDWYFDV
            WGQGTTVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG
            VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SDTKVDKKVE PKSCDKTHTC
            PPCPAPPVAG PSVFLFPPKP KDTLMISRTP EVTCVVVDVK HEDPEVKFNW YVDGVEVHNA
            KTKPREEEYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ
            VYTLPPSREE MTKNQVSLTC DVSGFYPSDI AVEWESDGQP ENNYKTTPPV LDSDGSFFLY
            SKLTVDKSRW EQGDVFSCSV LHEALHSHYT QKSLSLSPGK
            (Chain C)
            DIVLTQSPSS LSASVGDRVT ITCRASQSVD YDGDSYMNWY QQKPGKPPKL LIYAASELES
            GIPARFSGSG SGTDFTLTIS SLQPEDFATY YCQQSNEDPF TFGSGTKLEI KRTVAAPSVF
            IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
            STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
            (Disulfide bridge: A22-A96, A161-A227, A257-B230, A260-B233, A291-A351, A397-A455, B22-B98, B148-B204, B224-C218, B264-B324, B370-B428, C23-C92, C138-C198)
  TYPE      Peptide
CLASS       Antineoplastic
             DG02938  Immune checkpoint inhibitor
EFFICACY    Antineoplastic, Immune checkpoint inhibitor
  TYPE      Monoclonal antibody, bispecific antibody
TARGET      CTLA4 (CD152) [HSA:1493] [KO:K06538]
            LAG3 (CD223) [HSA:3902] [KO:K06565]
  PATHWAY   hsa04514(1493)  Cell adhesion molecules
            hsa04660(1493)  T cell receptor signaling pathway
BRITE       Drug groups [BR:br08330]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D12317  Bavunalimab
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Immune checkpoints
                CTLA4 (CD152)
                 D12317  Bavunalimab (USAN/INN)
               CD molecules
                LAG3 (CD223)
                 D12317  Bavunalimab (USAN/INN)
DBLINKS     CAS: 2329669-78-3
///
